Pharma firm Wockhardt will continue to strengthen its R&D capabilities to develop innovative and technologically advanced medicines, a top official has said.

Addressing the shareholders in the company's annual report, Wockhardt Managing Director Murtaza Khorakiwala said the firm has set up three world-class, multi-disciplinary R&D facilities in India, the UK and the US, which are engaged in studies and experiments to develop new drugs and novel drug delivery systems for tomorrow.

"We believe that the future lies in innovation, which will lead to quantum leaps in growth. We are determined to continue to focus on enhancing and strengthening our R&D capabilities," Khorakiwala said.